At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Percoffedrinol® +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Multiple Doses of BI 730357 on the Single Dose Pharmacokinetics of Caffeine, Warfarin, Omeprazole and Midazolam Administered Orally as a Cocktail in Healthy Subjects (an Open-label, Two-period Fixed Sequence Design Trial)
In Brief
A Phase 1 clinical trial evaluating Percoffedrinol®, Coumadin®, and 3 other interventions for Healthy. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The trial will be performed to assess the influence of BI 730357 on the pharmacokinetics of caffeine, warfarin, omeprazole and midazolam.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartDec 2020
First PostedDec 2020
Primary CompletionMar 2021
TodayJul 2026
First PostedDec 22, 2020
Enrollment StartDec 21, 2020
Primary CompletionMar 17, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.5 years ago
Interventions
Percoffedrinol®drug
Tablet
Coumadin®drug
Tablet
Antra MUPS®drug
Gastro-resistant tablet
Midazolam-ratiopharm®drug
Oral solution
BI 730357drug
Film-coated tablet